Financings Of The Fortnight: Recent IPO Slowdown Not Necessarily A Harbinger For A Bad 2014
This article was originally published in The Pink Sheet Daily
Executive Summary
Series A financing volume is up in recent years, suggesting that 2014 will be a strong year for biotechs opting to go public. Plus financing news from Atara Biotherapeutics, Crescendo Biologics, Acucela and TetraLogic.
You may also be interested in...
Biotech IPO Candidates Ramp Up To Get Out Before The Holidays
After a bit of a lull since September, there are seven biotechnology IPOs slated to get out in the next few weeks. But they are entering a tougher market than earlier in 2013, and some may not be quite the same quality.
Start-Ups, With An Eye On Success In Wet AMD, Tackle The Dry Form
“Early and primitive” is a term frequently used to describe drug development for dry AMD in discussions with experts. Several companies have brought products to Phase II trials, but none has met the efficacy endpoints. A new crop of start-ups is trying, driven by the huge unmet demand and emerging science.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.